VA2 Cost Effectiveness Analysis of Vaccination Programs With 10-Valent (PCV10) and 13-Valent (PCV13) Pneumococcal Vaccines in Bogotá, Colombia

  • Torres C
  • Jaramillo J
  • Coronell W
  • et al.
N/ACitations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

OBJECTIVES: Pneumococcus was responsible for more than 50% of the preventabledeaths in infants under 5 years of age according to the Pan American Health Organizationbefore the introduction of conjugate vaccines. The objective of this analysisis to evaluate the cost effectiveness of vaccinating the Colombian populationyounger than 2 years of age with 13-valent vaccine (PCV 13) in comparison to the10-valent or PHiD-CV vaccine (PCV 10) both in same schedule. METHODS: In orderto estimate the costs and the impact of the pneumococcal disease, a Markov modelsimulating vaccination and outcomes of 10 annual birth cohorts was adapted to theColombian conditions from the Health System perspective. The probabilities andthe costs were extracted from a literature review and tariff manuals applicable forColombia for January 2011, with costs presented in US$. The results in health areexpressed as number of cases of diseases and deaths prevented, as well as in termsof life years (LYs) and QALYs saved. Probabilistic sensitivity analyses were done.RESULTS: Over a 10 year period, vaccinating with PCV13 prevents 8,191 cases ofinvasive pneumococcal disease, 58,587 hospitalized pneumonia, 5,583 non complicatedpneumonia and 2,927 deaths, saving 70,640 LY's and 63,697 QALY'scompared to PCV10. PCV10 prevents 49,354 additional cases of acute otitis mediaversus PCV13. The total costs including vaccination costs and medical costsare US$ 89,608,061 less for PCV13 compared to PCV10 (US$ 2,365,043,131 vs. US$2,454,651,191). The model shows robustness in the sensibility analysis.CONCLUSIONS: The analysis suggests that vaccinating infants with PCV13 in Colombiais a cost-saving alternative in comparison with PHiD-CV. The results ineconomic and disease burden are substantial and they support the decision makingin favor of PCV13 for its high impact in public health.

Cite

CITATION STYLE

APA

Torres, C., Jaramillo, J., Coronell, W., Gutierrez, M. V., & Caceres, H. A. (2011). VA2 Cost Effectiveness Analysis of Vaccination Programs With 10-Valent (PCV10) and 13-Valent (PCV13) Pneumococcal Vaccines in Bogotá, Colombia. Value in Health, 14(7), A538. https://doi.org/10.1016/j.jval.2011.08.1533

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free